EGFR and non-small cell lung carcinoma: Our findings indicate that EGFR‐mutated NSCLC patients with BoM receiving first‐ or second‐generation EGFR–TKI are more likely to develop T790M resistance after TKI failure (47.4% vs. 33.9%, p = 0.042).